Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PF074 VEGF₁₆₅, Human, Recombinant

VEGF₁₆₅, Human, Recombinant MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Vascular Permeability Factor

PF074
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Purity
≥95% by SDS-PAGE

Products

Catalogue NumberPackaging Qty/Pack
PF074-10UG Plastic ampoule 10 μg
Description
OverviewRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions.
Catalogue NumberPF074
Brand Family Calbiochem®
SynonymsVascular Permeability Factor
References
ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
Soker, S., et al. 1998. Cell 92, 735.
Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
Brown, L., et al. 1992. Kidney International 42, 1457.
Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
Conn, G., et al. 1990. PNAS 87, 1323.
Leung, D.W., et al. 1989. Science 246, 1306.
Product Information
FormLyophilized
FormulationCarrier free.
PreservativeNone
Quality LevelMQ100
Applications
Data setup Error. Pagelet <collection_feature_application_id-PROLIF> not found.
Application NotesProliferation Studies
Biological Information
Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
Purity≥95% by SDS-PAGE
Physicochemical Information
ContaminantsEndotoxins: ≤100 pg/µg VEGF
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
PF074-10UG 07790788054014

Documentation

VEGF₁₆₅, Human, Recombinant SDS

Title

Safety Data Sheet (SDS) 

VEGF₁₆₅, Human, Recombinant Certificates of Analysis

TitleLot Number
PF074

References

Reference overview
Hashimoto, G., et al. 2002. J. Biol. Chem. In Press.
Soker, S., et al. 1998. Cell 92, 735.
Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
Brown, L., et al. 1992. Kidney International 42, 1457.
Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
Conn, G., et al. 1990. PNAS 87, 1323.
Leung, D.W., et al. 1989. Science 246, 1306.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision16-September-2008 RFH
SynonymsVascular Permeability Factor
ApplicationProliferation Studies
DescriptionRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions. Useful for proliferation assays; titrate for optimal results with individual cell types.
FormLyophilized
FormulationCarrier free.
Purity≥95% by SDS-PAGE
ContaminantsEndotoxins: ≤100 pg/µg VEGF
Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
SolubilityReconstitute lyophilized product in sterile PBS containing at least 0.1% human serum albumin or bovine serum albumin to ≥ 10 µg/ml. Make further dilutions in PBS, 0.1% BSA, HSA, or other carrier protein.
PreservativeNone
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
Soker, S., et al. 1998. Cell 92, 735.
Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
Brown, L., et al. 1992. Kidney International 42, 1457.
Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
Conn, G., et al. 1990. PNAS 87, 1323.
Leung, D.W., et al. 1989. Science 246, 1306.